Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review-Reference-Cited by-同舟云学术

Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review

Published:2020-06-29 Issue:6 Volume:45 Page:1363-1371
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Xu Yan¹,Li Qiang²,Ma Hai‐Yang¹,Sun Tao¹,Xiang Ruo‐Lan³,Di Fei¹⁴^ORCID

Affiliation:

1. Department of Neurosurgery Beijing Tiantan Hospital Capital Medical University Beijing China

2. Department of Neurosurgery Xinle City Hospital Xinle Hebei China

3. Department of Physiology and Pathophysiology Peking University School of Basic Medical Sciences Beijing China

4. Department of Neurosurgery ZhangJiakou First Hospital Zhangjiakou Hebei China

Funder

Beijing-Tianjin-Hebei Collaborative innovation community construction project

Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13228

Reference28 articles.

1. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11)

2. The biology of VEGF and its receptors

3. Bevacizumab in recurrent high-grade pediatric gliomas

4. Angiogenesis: an organizing principle for drug discovery?

5. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CPT-11 mitigates autoimmune diseases by suppressing effector T cells without affecting long-term anti-tumor immunity;Cell Death Discovery;2024-05-04

2. Recent advancements in Irinotecan-loaded nanomaterials as a smart drug delivery system for cancer therapy: A state-of-art-review;Inorganic Chemistry Communications;2024-03

3. Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss;Biomedicines;2022-12-23

4. The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma;Cancers;2022-01-28

5. Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review;Neuro-Oncology Advances;2022-01-01